Related Experiment Video
Updated: Aug 27, 2025
Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
Published on: August 31, 2022
Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma
Mengjiao Xu1, Liu Yang1, Yanjie Lin2
1Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, 8 Jingshun East Street, Chaoyang District, Beijing, 100015, China.
Abstract:
Primary liver cancer has become the second most fatal cancer in the world, and its five-year survival rate is only 10%. Most patients are in the middle and advanced stages at the time of diagnosis, losing the opportunity for radical treatment. Liver cancer is not sensitive to chemotherapy or radiotherapy. At present, conventional molecularly targeted drugs for liver cancer show some problems, such as short residence time, poor drug enrichment, and drug resistance. Therefore, developing new diagnosis and treatment methods to effectively improve the diagnosis, treatment, and long-term prognosis of liver cancer is urgent. As an emerging discipline, nanobiotechnology, based on safe, stable, and efficient nanomaterials, constructs highly targeted nanocarriers according to the unique characteristics of tumors and further derives a variety of efficient diagnosis and treatment methods based on this transport system, providing a new method for the accurate diagnosis and treatment of liver cancer. This paper aims to summarize the latest progress in this field according to existing research and the latest clinical diagnosis and treatment guidelines in hepatocellular carcinoma (HCC), as well as clarify the role, application limitations, and prospects of research on nanomaterials and the development and application of nanotechnology in the diagnosis and treatment of HCC.
Insights
Nanobiotechnology offers new ways to diagnose and treat liver cancer, improving patient outcomes. This approach uses targeted nanomaterials to overcome limitations of current therapies for hepatocellular carcinoma (HCC).
Area of Science:
- Nanobiotechnology
- Oncology
- Materials Science
Background:
- Primary liver cancer, particularly hepatocellular carcinoma (HCC), has a low five-year survival rate (10%) and is often diagnosed at advanced stages.
- Conventional treatments like chemotherapy and radiotherapy are often ineffective for liver cancer, and existing targeted therapies face challenges like poor drug enrichment and resistance.
- There is an urgent need for innovative diagnostic and therapeutic strategies to improve the prognosis of liver cancer patients.
Purpose of the Study:
- To summarize the latest advancements in nanobiotechnology for diagnosing and treating hepatocellular carcinoma (HCC).
- To review the role, limitations, and future prospects of nanomaterials and nanotechnology in HCC management.
- To align the summary with current clinical guidelines for HCC diagnosis and treatment.
Main Methods:
- Review of existing research on nanobiotechnology applications in liver cancer.
- Analysis of current clinical diagnosis and treatment guidelines for hepatocellular carcinoma (HCC).
- Focus on the development and application of targeted nanocarriers and nanomaterials for HCC therapy.
Main Results:
- Nanobiotechnology provides a novel platform for developing highly targeted nanocarriers, addressing limitations of conventional treatments.
- These nanocarriers can be engineered based on tumor-specific characteristics for improved drug delivery and efficacy.
- Emerging nanotechnology-based methods offer potential for accurate diagnosis and effective treatment of HCC.
Conclusions:
- Nanobiotechnology presents a promising frontier for advancing the diagnosis and treatment of hepatocellular carcinoma (HCC).
- Targeted nanomaterials offer potential solutions to overcome drug resistance and improve therapeutic outcomes in liver cancer.
- Further research and development in nanotechnology are crucial for realizing its full potential in improving long-term prognosis for HCC patients.
More Related Videos
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
